JUPITER NEUROSCIENCES

JUPITER NEUROSCIENCES is a US-based clinical-stage R&D pharmaceutical company. Its product, JOTROL™, has many potential indications for rare diseases, among which we primarily target Mucopolysaccharidosis Type 1, Friedreich's Ataxia, MELAS, and ALS, which is in the early stage of development. In larger disease areas, we mainly focus on Mild Cognitive Impairment/Early Alzheimer’s Disease with TBI/Concussion and Covid-19, which is also in the early stage of development.